TD Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.5M | Buy |
|
|||||
|
2025
Q1 | $13.6M | Buy |
|
|||||
|
2024
Q4 | $13.9M | Sell |
|
|||||
|
2024
Q3 | $13.7M | Sell |
|
|||||
|
2024
Q2 | $19.3M | Sell |
|
|||||
|
2024
Q1 | $19.8M | Buy |
|
|||||
|
2023
Q4 | $13.7M | Buy |
|
|||||
|
2023
Q3 | $6.27M | Buy |
|
|||||
|
2023
Q2 | $3.33M | Sell |
|
|||||
|
2023
Q1 | $3.73M | Sell |
|
|||||
|
2022
Q4 | $4.56M | Sell |
|
|||||
|
2022
Q3 | $14.1M | Sell |
|
|||||
|
2022
Q2 | $22.7M | Sell |
|
|||||
|
2022
Q1 | $25.4M | Sell |
|
|||||
|
2021
Q4 | $24.2M | Buy |
|
|||||
|
2021
Q3 | $15.5M | Sell |
|
|||||
|
2021
Q2 | $16M | Sell |
|
|||||
|
2021
Q1 | $19M | Buy |
|
|||||
|
2020
Q4 | $17.3M | Buy |
|
|||||
|
2020
Q3 | $16.8M | Buy |
|
|||||
|
2020
Q2 | $20.3M | Buy |
|
|||||
|
2020
Q1 | $12.8M | Sell |
|
|||||
|
2019
Q4 | $18.2M | Buy |
|
|||||
|
2019
Q3 | $14.1M | Buy |
|
|||||
|
2019
Q2 | $7.04M | Sell |
|
|||||
|
2019
Q1 | $7.59M | Sell |
|
|||||
|
2018
Q4 | $6.93M | Sell |
|
|||||
|
2018
Q3 | $16.8M | Buy |
|
|||||
|
2018
Q2 | $12.9M | Buy |
|
|||||
|
2018
Q1 | $10.7M | Buy |
|
|||||
|
2017
Q4 | $9.78M | Sell |
|
|||||
|
2017
Q3 | $9.32M | Sell |
|
|||||
|
2017
Q2 | $7.2M | Buy |
|
|||||
|
2017
Q1 | $3.79M | Sell |
|
|||||
|
2016
Q4 | $5.14M | Sell |
|
|||||
|
2016
Q3 | $10.1M | Sell |
|
|||||
|
2016
Q2 | $10.4M | Sell |
|
|||||
|
2016
Q1 | $9.17M | Sell |
|
|||||
|
2015
Q4 | $13.5M | Buy |
|
|||||
|
2015
Q3 | $8.88M | Sell |
|
|||||
|
2015
Q2 | $11.4M | Sell |
|
|||||
|
2015
Q1 | $9.65M | Buy |
|
|||||
|
2014
Q4 | $4.74M | Buy |
|
|||||
|
2014
Q3 | $3.11M | Sell |
|
|||||
|
2014
Q2 | $3.07M | Sell |
|
|||||
|
2014
Q1 | $3.49M | Buy |
|
|||||
|
2013
Q4 | $1.66M | Sell |
|
|||||
|
2013
Q3 | $2.04M | Buy |
|
|||||
|
2013
Q2 | $1.95M | Buy |
|